钇-90放射栓塞治疗孤立不可切除肝细胞癌的LEGACY研究
LEGACY为多中心单臂回顾性研究,纳入162例孤立不可切除HCC(≤8cm、Child-Pugh A、ECOG 0-1),采用钇-90玻璃微球放射栓塞。盲法独立中心评估的客观缓解率为88.3%(CI: 82.4-92.4),62.2%的患者缓解持续时间≥6个月,3年总生存率为86.6%。
要点
- 孤立不可切除HCC(≤8cm)经钇-90放射栓塞后客观缓解率达88.3%。
- 62.2%的患者缓解持续时间≥6个月,3年总生存率86.6%。
- 21.0%和6.8%的患者分别将放射栓塞作为移植或切除的新辅助治疗。
核心结论
- 在孤立不可切除HCC≤8cm患者中,钇-90放射栓塞观察到有临床意义的缓解率和延长的缓解持续时间。
研究设计与样本
- 多中心、单臂、回顾性研究,在三个中心纳入2014至2017年间连续接受放射栓塞的符合条件的HCC患者。
- 纳入标准为孤立HCC≤8cm、Child-Pugh A肝硬化、ECOG体能状态0-1,共纳入162例患者。
- 主要终点为基于mRECIST的客观缓解率和缓解持续时间,由盲法独立中心评估。
主要发现
- 盲法独立中心评估的中位肿瘤大小为2.7cm(范围:1-8)。
- 客观缓解率(最佳缓解)为88.3%(CI: 82.4-92.4)。
- 62.2%(CI: 54.1-69.8)的患者缓解持续时间≥6个月。
- 中位随访时间为29.9个月(反向Kaplan-Meier法)。
- 3年总生存率全部患者为86.6%,新辅助后切除或移植患者为92.8%。
临床怎么用
- 对于孤立不可切除HCC≤8cm、Child-Pugh A、ECOG 0-1的患者,钇-90放射栓塞可作为治疗选择。
- 放射栓塞可作为移植或切除的新辅助治疗,研究中21.0%患者用于移植前、6.8%用于切除前。
局限性
- 本研究为单臂回顾性研究,非随机对照设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Locoregional therapies, including yttrium-90 radioembolization, play an important role in the treatment of unresectable HCC. The aim of the LEGACY (Local radioEmbolization using Glass Microspheres for the Assessment of Tumor Control with Y-90) study was to evaluate objective response rate (ORR) and duration of response (DoR) in patients with solitary unresectable HCC treated with yttrium-90 glass microspheres. APPROACH AND RESULTS: LEGACY is a multicenter, single-arm, retrospective study conducted at three sites that included all eligible, consecutive patients with HCC treated with radioembolization between 2014 and 2017. Eligibility criteria included solitary HCC ≤ 8 cm, Child-Pugh A cirrhosis, and Eastern Cooperative Oncology Group performance status 0-1. Primary endpoints were ORR and DoR based on modified Response Evaluation Criteria in Solid Tumors in the treated area (localized), as evaluated by blinded, independent, central review. Radioembolization was performed with intent of ablative-level dosimetry in a selective fashion when possible. Overall survival was evaluated using Kaplan-Meier and multivariate Cox proportional hazards. Among the 162 patients included, 60.5% were Eastern Cooperative Oncology Group 0, and the median tumor size was 2.7 cm (range: 1-8) according to blinded, independent, central review. Radioembolization served as neoadjuvant therapy for transplantation or resection in 21.0% (34 of 162) and 6.8% (11 of 162) of patients, respectively, and as primary treatment for all others. Median follow-up time was 29.9 months by reverse Kaplan-Meier. ORR (best response) was 88.3% (CI: 82.4-92.4), with 62.2% (CI: 54.1-69.8) exhibiting a DoR ≥ 6 months. Three-year overall survival was 86.6% for all patients and 92.8% for those neoadjuvant patients with resected or transplanted liver. CONCLUSIONS: In this multicenter study of radioembolization, clinical meaningful response rates and prolonged DoR were observed in the treatment of unresectable, solitary HCC ≤ 8 cm.
引用
- Salem R, Johnson GE, Kim E, et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology. 2021. PMID: 33739462. doi:10.1002/hep.31819
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。